Miniatura

Fitxers

blooda_adv-2025-016661-main.pdf (515.57 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-07-16

Llicència de publicació

cc-by-nc-nd (c) American Society of Hematology, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223775

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1182/bloodadvances.2025016661

Resum

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, although real-world evidence studies have not consistently confirmed these results. We aimed to describe real-world outcomes of R/R DLBCL treated with T/L in Spain. A total of 99 patients received at least 1 dose of tafasitamab (intent-to-treat [ITT] cohort), with 83 completing at least 1 full cycle of T/L (efficacy cohort). Respectively for ITT and efficacy cohorts, at a median follow-up of 19.2 and 21.6 months, the overall response rate was 51% and 61% (complete response [CR], 35% and 42%). Median duration of response was not reached, and patients achieving a CR had excellent outcomes. The median progression-free survival (PFS) was 4.9 and 10.9 months, and overall survival (OS) was 12.2 and 21.8 months, respectively for both ITT and efficacy cohorts. Neither age nor cumulative illness rating score influenced survival. Better PFS was obtained in first/second relapse but only poor Eastern Cooperative Oncology Group performance status 2 to 4, double-hit lymphoma, and those with refractory/progressing disease after the previous therapy, were independently associated with worse PFS. Treatment was generally well tolerated, with manageable toxicity. Relative dose intensity of lenalidomide significantly affected response, PFS, and OS. In summary, T/L is both well tolerated and effective, irrespective of age or comorbidities. Our findings provide valuable insights into the real-world application of T/L and reinforce its role as a key treatment option for patients with R/R DLBCL.

Matèries

Immunosupressió, Assaigs clínics, Leucèmia aguda

Matèries (anglès)

Immunosuppression, Clinical trials, Acute leukemia

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GUTIERREZ, Antonio, ZEBERIO, Izaskun, PENALVAR, Francisco javier, MARTINEZ BARRANCO, Pilar, PÉREZ LEÓN, Sandra, MORILLO, Daniel, MARTIN, Xabier, NICOLÁS, Concepción, FERRERO, Ainara, JIMÉNEZ UBIETO, Ana, BASTOS OREIRO, Mariana, DAVILA VALLS, Julio, VICTORIA CALLE, Maria, PÉREZ SALA, María, RODRIGUEZ, Guillermo, ALONSO, Aranzazu, GARCIA NOBLEJAS, Ana, SANCHEZ ARGÜELLO, Diana, KNIGHT, Teresa, FERNANDEZ, Angeles, LÓPEZ MARÍN, Javier, PEREZ DE OTEYZA, Jaime, GONZALEZ DE VILLAMBROSIA, Sonia, PÉREZ, Elena, MARIN, Alejandro, BELEN NAVARRO, Maria, FERNÁNDEZ, Rubén, GÓMEZ PRIETO, Pilar, ANTONIO HUESO, Jose, PEÑARRUBIA PONCE, Maria jesus, BRAVO, Pilar, GARCÍA BELMONTE, Daniel, NUEZ, Haridian de la, NISTAL, Sara, ABRISQUETA, Pau, IBAÑEZ, Fernanda, PALOMERA BERNAL, Luis, DONATO, Eva, PROVENCIO, Andrea, INFANTE, Maria stefania, GONZÁLEZ BARCA, Eva. Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO. _Blood Advances_. 2025. Vol. 9, núm. 19, pàgs. 4924-4935. [consulta: 25 de febrer de 2026]. ISSN: 2473-9537. [Disponible a: https://hdl.handle.net/2445/223775]

Exportar metadades

JSON - METS

Compartir registre